🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Hansa Biopharma AB (publ) (STO:HNSA)
Sweden flag Sweden · Delayed Price · Currency is SEK
45.14
-2.18 (-4.61%)
Nov 20, 2026, 5:29 PM CET
← View all transcripts

Earnings Call: Q3 2026

Nov 11, 2026

Summary

Q3 revenue reached SEK 143m, with the SERB upfront driving a stronger balance sheet. U.S. launch preparations advanced ahead of a potential December FDA decision, while imlifidase clinical data and the GBS pipeline progressed.

Operator

Good day, and thank you for standing by. Welcome to the Hansa Biopharma interim report for January to September 2026 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star, one, and one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star, one, and one again. Please be advised today's conference is being recorded. I'd now like to hand the conference over to your first speaker today, Renée Aguiar-Lucander. Please go ahead.

Renée Aguiar-Lucander
CEO, Hansa Biopharma

Thank you very much. Good afternoon, good morning to everybody. Welcome to the Hansa Biopharma conference call to review the Q3 results for 2026. I'm Renée Aguiar-Lucander, CEO for Hansa Biopharma, and joining me today is Maria Törnsén, Chief Operating Officer and U.S. President, Richard Philipson, Chief Medical Officer, and Adam Cutler, Chief Financial Officer. Next page, please. Please allow me to draw your attention to the fact that we'll be making forward-looking statements during this presentation, and you should therefore apply appropriate caution. Next page, please. This is the agenda for today's call, and I've already introduced the various speakers. Please turn to the next slide. Q3 was a quarter of execution and a significant strengthening of our balance sheet. We closed the out-licensing deal in Europe and MENA and subsequently received the upfront payment, which enabled us to delever and significantly bolster our cash balance.

In the U.S., our pre-commercial activities are ongoing, and we're continuing to make great progress across all relevant aspects of launch readiness in advance of a potential approval in December, for which Maria will provide more details. We also advanced our pipeline with events taking place mainly after the quarter end, with continued advances of our Genethon collaboration, oral presentations at both TTS and ASN, and the submission of our IND and GBS to the FDA. Richard will provide some more details on these scientific presentations later in the call. Next page, please. Just a quick reminder of the key terms of the out-licensing transaction due to its relevant impact on the Q3 results.

At this time, the market authorization holdership for Idefirix has been transferred both in Europe as well as in the U.K. to SERB, and our transition activity focus is now mainly on clinically related activities, considering the transfer of the MAH responsibility, and on the filing to convert the conditional approval of Idefirix to full approval to the EMA, which is on track to be submitted on time in Q4. With that, I'm going to hand over to Maria to take us through some of the commercial preparations in the U.S.

Maria Törnsén
COO and U.S. President, Hansa Biopharma

Thank you very much, Renée. Next slide, please. I will start with the opportunity. The U.S. kidney transplant market is large and growing, and a significant part of that need is still unmet, especially for highly sensitized patients where imlifidase can make transplant possible. Let me begin with the circles on the left. There are about 560,000 people on dialysis in the U.S. About 100,000 of them are on the kidney transplant wait list. Within that group, the patients with the greatest need are the highly sensitized ones, measured by CPRA, which is a measure of HLA sensitization. About 15,000 have a CPRA above 80%, about 7,000 have a CPRA above 98%, and about 3,500 have a CPRA above 99%, and this was the population included in the U.S. ConfIdeS study. The more sensitized the patient is, the harder it is to find a matching organ.

The panel on the right shows that the wait list is growing. About 27,000 transplants are done each year, and 80% of those use deceased donor organs. But about 45,000 people are added to the wait list every year, so the list keeps growing. About 10,000 people die each year or become too sick to be transplanted, and for patients with a CPRA above 99%, the wait is more than seven years. One more number shows that the system is not working as well as it could. About 9,000 recovered kidneys are discarded each year, and 60% of those, or more than 5,000, are discarded because no recipient could be located and the list was exhausted. We also see the need directly. We get requests from key opinion leaders and requests for compassionate use, and both confirm that the unmet medical need is real.

To sum up, a large population is waiting, the wait list keeps growing, and the most sensitized patients have very few options. Next, I will show where these patients are treated and how the U.S. transplant market is structured. Next slide, please. Now that we've seen the size of the unmet need, let's look at where these patients are treated. The U.S. transplant market is highly concentrated. There are about 200 transplant centers, but about 100 of them represent 80% of the U.S. transplant volume, so a focused effort reaches most of the market. Within that group, the ConfIdeS centers stand out. They account for 25% of annual kidney transplant volume. The map shows where they are, and they are spread across the whole country, the West Coast, the Midwest, the South, the Northeast, and the Mid-Atlantic. These are the leading institutions in the U.S.

They include many of the best-known academic medical centers, and they set the standard in kidney transplantation. They treat the largest numbers of patients. They handle the most complex cases, including the highly sensitized patients we talked about on the previous slide. The key message is the market is very concentrated, and by working closely with a limited number of leading centers, we can reach a large share of the kidney transplant volume, and we can launch efficiently. With this concentrated market and these leading centers in mind, let me now walk you through the critical pre-launch activities that we completed in the last few months to get ready for launch. Next slide, please. We made good progress in the last few months. Three milestones carry the most weight. We submitted our NTAP application in October of 2026.

We selected our distribution partners, and we have our U.S. leadership team in place. Let me take each in turn and then cover our engagements with physicians and patients. First, NTAP. We submitted the application in October 2026. If approved, it would add a further payment pathway for imlifidase. Second, distribution. We have selected a third-party logistics provider and a specialty distributor who will be responsible for distributing imlifidase in the U.S. The state licensing process has also started, and the first state has approved us, and we are submitting in additional states ahead of the PDUFA date. We are also on track for product availability in Q1 2027, subject to FDA approval. Third, our U.S. team. We hired our head of U.S. sales, who has 27 years of experience. He has launched 10 hospital products and has been through 13 launches in total.

We have completed hiring for the other U.S. home office roles in commercial and G&A, and we've also started recruiting the commercial field team, and we expect to onboard an additional 16 commercial representatives in the first week of January 2027, subject to FDA approval. Alongside these milestones, we continue engaging physicians and patients. We presented ConfIdeS at TTS and ASHI. We also presented the European phase III data for the first time at ASN. At TTS, Professor Couzi presented the French experience. 99 patients have now been transplanted with imlifidase in France. This matters because it gives us real-world evidence from commercial use, which shows how imlifidase performs in routine clinical practice outside of a clinical trial. We also launched a disease state educational campaign for healthcare providers and patients, and we engaged with the patient advocacy leaders at the AAKP Summit, the REIMAGINE Symposium, and at ASN.

To sum up, we have built the foundation. The NTAP application is in, the access and distribution pathway is in place, and the team to execute is being assembled, and our data and message are out with the community. Next, I will explain why broad market access is the key value driver. Next slide, please. Securing broad market access is a key value driver for the launch, so let me walk through the three main payer groups and then the NTAP timeline. The largest group is Medicare Fee-for-Service at about 40% of patients. ESRD patients are eligible, but they must apply, and once they're covered, they can go to any Medicare center. Hospitals are paid through DRG and outlier payments, so each hospital's cost-to-charge ratio affects its transplant economics. This is also where NTAP, the New Technology Add-On Payment, would apply if approved.

Next is Medicare Advantage at about 25% of patients. These are commercially managed plans contracted with Medicare. Patients must first qualify for Medicare and then use the plan's provider network, and the plans must cover medically necessary transplant services. Prior authorizations are similar to commercial plans, but they are consistent across all plans. The third group is the commercial plans. Patients must here use a provider-specific network. A center of excellence is frequently required, and coverage varies by employer and plan design. The key point is that contracted rates are materially higher than Medicare. Across all three groups, we expect broad coverage over time. Coverage decisions may take some time to come through, and we expect them to build gradually in parallel with the NTAP process. Now to the NTAP timeline. We submitted our application in October of 2026.

The CMS town hall is on December 9 and 10, 2026, and we expect the proposed Inpatient Prospective Payment System, IPPS, rule in April of 2027, and the final rule on August 1, 2027, which would make NTAP effective October 1, 2027. In short, we need broad access across all three payer groups, and NTAP would add a further payment pathway for imlifidase. Next, I will show you how we are preparing the transplant centers to be ready for launch. Next slide, please. We are approximately five weeks away from the PDUFA date, and our pre-launch efforts are focused on getting the transplant centers ready, both clinically and operationally. On the clinical side, our medical field team is engaging with the top 100 centers, which represent 80% of the U.S. kidney transplant volume. To date, we have engaged close to 90% of these tier one centers.

We are gathering insights on how these centers currently manage highly sensitized transplant patients, and we are working to understand their HLA lab capability and their current approach to delisting. In each center, we are identifying the clinical champion, typically a transplant surgeon or nephrologist, and so far, we have identified an influential clinical champion in approximately 40 centers. We are also identifying the stakeholders in the multidisciplinary team and their role in the treatment of highly sensitized patients. On the operational and financial side, our field market access team is engaging with the same top 100 centers. We are identifying financial stakeholders within each center, and we are working to understand the structure of the P&T committee and how imlifidase will be evaluated. We are also engaging with the transplant center financial coordinator, who is responsible for billing and coding.

In parallel, we will have a national account director team who will be engaging with the commercial plans. All of this is, of course, subject to FDA approval. With the centers and payers being prepared, I will close by summarizing why imlifidase has the potential to change the treatment paradigm. Next slide, please. If approved, we believe that imlifidase has the potential to change the treatment paradigm for highly sensitized kidney transplant patients in the U.S. These are patients who have waited years without access to a compatible donor, and imlifidase addresses one of the most challenging unmet needs in kidney transplantation. By significantly and predictably reducing donor-specific antibodies, it enables a transplant that was previously not possible. The clinical benefit has been consistent and reproducible across ConfIdeS, PAES, and the European real-world data. Our phase II data published in 2025 also shows durable transplant outcomes over five years.

The interest from the field is already clear. We are receiving multiple compassionate use requests from transplant centers across the U.S., and our medical team is receiving medical information requests about imlifidase and the recent clinical data. While other desensitization approaches have historically been explored, none are approved or have shown to be effective in deceased donor transplantation. Imlifidase offers a rapid and reliable reduction of antibodies to enable a transplant, and it has the potential to create a new clinical paradigm for desensitization. We are very excited about this opportunity, and if approved, we will be launch-ready at PDUFA, and we anticipate imlifidase being available to order in the U.S. in Q1 2027. With that, I will hand it over to our Chief Medical Officer, Richard Philipson. Richard?

Richard Philipson
CMO, Hansa Biopharma

Thanks, Maria. Today, I am going to focus on recent presentations of imlifidase data. Next slide. I would like to start by discussing the results of the ConfIdeS study evaluating the use of imlifidase in highly sensitized kidney transplant patients that were presented recently in Sydney at the 31st International Congress of The Transplantation Society by Dr. Robert Montgomery, Director of the NYU Langone Transplant Institute. Dr. Montgomery was the national coordinating investigator for the ConfIdeS study and gave the presentation on behalf of the ConfIdeS study group. While I discussed Dr. Montgomery's ATC presentation at the previous quarterly update, I would like to focus on some additional study outcomes that Dr. Montgomery included in his Sydney presentation. Next slide. I think it is always worth starting by reviewing the design of the ConfIdeS study, which is illustrated on this slide.

Patients considered potential candidates for the study were consented and entered the pre-screening period. One or more unacceptable antigens were delisted from the patient's HLA profile to increase the likelihood of the patient receiving an organ offer. When an organ offer was received, patients entered screening and underwent a final evaluation of eligibility. Eligible patients were then randomized to the imlifidase arm or the control arm in a 1:1 ratio. The period of follow-up in the study was 12 months from the time of randomization. Patients randomized to the imlifidase arm accepted the organ offer and were treated with imlifidase. If treatment resulted in crossmatch conversion from positive to negative, then patients were transplanted and entered follow-up.

Patients randomized to the control arm either accepted the organ offer or were treated with non-approved desensitization determined by the site practice and then proceeded to transplant, or the organ offer was rejected, and the patient waited for a more compatible organ offer or offers later in the 12-month follow-up period. Next slide. When looking at the transplantation step itself, it is particularly striking that 28 patients in the imlifidase arm were transplanted within 24 hours of imlifidase treatment, 27 with a randomization organ offer and one patient with a subsequent organ offer. In comparison, only three patients in the control arm were transplanted at the time of randomization, with an additional 12 patients transplanted at a later time point. Also noteworthy is that there was a marked difference in time to transplantation between the two treatment groups.

In the imlifidase arm, the mean time from randomization to transplantation was 1.9 days, whereas in the control arm, it was 96.2 days. This further highlights the challenge of transplanting highly sensitized patients when only experimental desensitization treatments are available. Next slide. Here we see the mean eGFR for the imlifidase and control arms calculated using the MDRD formula and plotted over the 12-month period from randomization. At 12 months, eGFR was 51.5 mLs per minute in the imlifidase arm, compared with 19.3 mLs per minute in the control arm, resulting in a statistically significant and clinically relevant difference of 32.2 mLs per minute. Next slide. Of the 32 patients randomized in the imlifidase arm, five were dialysis-dependent at the end of the study, comprising four patients who were not transplanted and one patient who died from disseminated adenovirus infection on study day 72.

In comparison, in the control arm, 18 patients were dialysis-dependent at 12 months, which included the 17 patients who were never transplanted and one patient who had a transplant nephrectomy approximately three months after transplantation. This difference in dialysis dependency at 12 months was statistically significant in favor of the imlifidase arm. When eGFR outcomes at 12 months in transplanted patients are presented in categories, 42% of transplanted patients in the imlifidase arm had an eGFR of at least 60 mLs per minute, and more than 90% of patients had an eGFR of at least 30 mLs per minute. In contrast, 40% of patients in the control arm had an eGFR less than 30 mLs per minute at 12 months, compared to only 8% of patients in the imlifidase arm. Next slide.

The incidence of antibody-mediated rejection during the 12-month follow-up period of the study was 57% in the imlifidase arm and 46% in the control arm. Importantly, no grafts in the imlifidase arm were lost due to AMR, and the presence of AMR did not impact kidney function. This is clearly illustrated in the graphic on the right of this slide. Transplanted patients in the imlifidase arm are presented in blue, with patients with and without AMR presented separately, clearly demonstrating that eGFR was similar in the two categories. Next slide. With respect to patient survival and adverse events, there was one patient death during the 12-month follow-up period in the imlifidase arm. Adverse events and serious adverse events reflected post-transplant complications in keeping with current immunosuppressive practice and were consistent with previous clinical trial experience.

No imlifidase infusion was discontinued due to an adverse event, and no new safety signals were detected. Next slide. Now I'd like to move on to the results of the post-authorization efficacy and safety study, or PAES study, conducted in Europe. The results of this study will form the basis of an application to convert the conditional approval of imlifidase in kidney transplantation to full approval in Europe. These results were presented by Dr. Oriol Bestard from the Vall d'Hebron Barcelona Hospital on behalf of the PAES investigator group at the recent American Society of Nephrology annual conference in Denver. Next slide. I think it's helpful to provide a brief recap of the study design before getting into the results. There were three separate cohorts in this study.

The first cohort comprised patients enrolled in the imlifidase treatment group who were highly sensitized and had the highest unmet medical need based on the local kidney allocation system. Patients in this cohort underwent a delisting step at pre-screening to increase the likelihood of receiving a donor organ offer. When an organ offer was received, if the patient was crossmatch positive to the organ, then the patient proceeded to treatment with imlifidase and transplantation, subject to meeting required eligibility criteria and converting from crossmatch positive to negative. It was planned to enroll 50 patients into this treatment group. There were two non-comparative reference cohorts. It's important to note that patients were not randomized to these reference cohorts, and therefore no statistical comparisons have been made between the imlifidase treatment cohort and the reference cohorts.

Furthermore, patients in these two reference cohorts have different baseline characteristics when compared with the imlifidase treatment cohort. The non-comparative concurrent reference cohort comprised 50- 100 contemporaneous kidney transplant patients enrolled at the same study sites at approximately the same time as patients enrolled in the imlifidase treatment cohort. These patients were not sensitized and had a negative crossmatch to the deceased donor organ offer. The rationale for inclusion of this reference group was to understand outcomes at the same sites when undertaking compatible kidney transplant. Finally, the non-comparative historical reference cohort comprised 100 kidney transplanted patients randomly selected from a patient registry from 2010 onwards. Selection of patients was performed by the registry administrators and was completed prior to the start of enrollment of the main study.

Patients in this cohort were sensitized, but to a lesser degree than the patients in the imlifidase treatment group, and were crossmatch negative to the donor organ offer. Again, to emphasize, the primary objective to determine the one-year graft failure-free survival in highly sensitized kidney transplant patients applies to the imlifidase treatment group only. Next slide. In summary, all patients enrolled into the study were male or female, aged 18- 75 years, with an ABO-compatible deceased donor aged 10 - 70 years. Patients included in the imlifidase cohort were highly sensitized, whereas patients in the non-comparative concurrent reference cohort were not sensitized, and patients in the comparative historical reference cohort were sensitized, but to a lesser degree than the imlifidase cohort. Patients in the imlifidase cohort were crossmatch positive to the donor organ offer, whereas patients in the other two cohorts were crossmatch negative.

Patients in the historical cohort were transplanted in Europe during the period 2010- 2017. Next slide. The baseline characteristics of the imlifidase and concurrent reference cohorts are summarized in this table. Whilst most of the baseline characteristics are broadly similar in the two cohorts, it's worth noting the patients in the imlifidase cohort had been on dialysis for a median of 9.1 years, compared to a median of only 1.5 years in the concurrent reference cohort. Also noteworthy is that 88% of patients in the imlifidase cohort had had at least one previous transplant, compared to 11.1% of patients in the control cohort. Furthermore, 12% of patients in the imlifidase cohort had had three or more transplants. Next slide. The main outcomes in the study are summarized in this slide, and these have been presented previously.

In the imlifidase cohort, graft failure-free survival was 90%, patient survival was 98%, and death-censored graft survival was 92%. At 12 months after transplantation, median eGFR in the imlifidase cohort was 51 ml per minute. As can be seen from the table, these results are in line with what was seen in both the concurrent and the historical reference cohorts. Next slide. When looking at eGFR over the period of follow-up, patients in the imlifidase cohort recovered kidney function rapidly in the first 30 days after transplantation, and thereafter, kidney function remained stable through to 12 months. While proteinuria is seen in the initial period after transplantation, this declines over time, such that after 12 months, levels of proteinuria are similar in the imlifidase and concurrent reference cohorts. Next slide.

A total of 28 patients in the imlifidase treatment cohort experienced antibody-mediated rejection during the 12-month follow-up period after transplantation, which is consistent with what has been seen in other imlifidase trials in highly sensitized kidney transplant patients. As can be seen from the Kaplan-Meier estimate of risk, most episodes of AMR occurred in the first 30 days after transplantation. It's also important to note that eGFR in patients with AMR was similar to eGFR in patients without AMR during the follow-up period after imlifidase treatment and transplantation. Most importantly, no graft was lost due to AMR. Next slide. When looking at safety, imlifidase was well tolerated, and patient survival was 98%. Safety profile of imlifidase was consistent with current immunosuppressive practice and previous trial experience. No imlifidase infusion was interrupted or discontinued, no new safety signals were detected in the trial. Next slide.

Turning finally to our program in Guillain-Barré syndrome. Next slide. As discussed previously, HNSA-5487 is our next-generation IgG-cleaving enzyme generated from our in-house platform, which produces rapid and robust IgG reduction by more than 95% within a few hours after administration, and to which there is a significantly reduced anti-drug antibody response. We intend to develop HNSA-5487 in Guillain-Barré syndrome, and as part of our preparations, we submitted a comprehensive pre-IND briefing package to FDA in Q1 2026, on which we received feedback in Q2 2026. Based on this feedback and the subsequent interaction with FDA in Q3 2026, we submitted an IND for a phase IIa study in GBS, which incorporated FDA feedback on the 20th of October 2026. This will be a single ascending dose study in 16 patients with GBS, with enrollment of the first patient anticipated in Q1 2027.

Based on favorable outcomes from this phase IIa study, the development plan is expected to continue with a single pivotal phase III registrational study. I'd now like to hand over to Adam Cutler, Hansa's Chief Financial Officer.

Adam Cutler
CFO, Hansa Biopharma

Thank you, Richard. Next slide, please. Total revenue for Q3 2026 was SEK 143 million. This was driven primarily by license revenue under the SERB agreement of SEK 122 million, part of the EUR 110 million upfront payment received in July that is being recognized on a straight-line basis through December of 2028. Next slide, please. For Q3 2026, SG&A expenses totaled approximately SEK 148 million and were up compared to Q3 2025 SG&A of SEK 88 million. The increase was driven primarily, which was driven by increased costs associated with the preparation for the expected U.S. market launch, costs associated with the SERB transaction, as well as costs related to preparation for a potential U.S. listing. R&D expenses in Q3 2026 totaled approximately SEK 65 million and were down 7% versus Q3 2025.

In Q3, the loss from operations was SEK 139 million compared to SEK 148 million in Q3 of 2025. Next slide, please. Cash flow and the cash balance both benefit from the EUR 110 million upfront payment that we received from SERB in July, and cash flow from operations in Q3 2026 totaled SEK 964 million, compared to SEK -107 million in the comparable period last year. Cash and cash equivalents in Q3 of 2026 of SEK 1.3 billion, or approximately $135 million at the end of the period. Headcount for the period totaled 132, compared to 133 in Q3 of 2025, and 153 at the end of Q2 2026. Q3 2026 headcount reflects both hiring and preparation for expected U.S. commercialization, as well as the transfer of personnel to SERB due to the out-licensing transaction.

Now I'd like to turn the presentation back to Renée for closing remarks and the Q&A portion of the call.

Renée Aguiar-Lucander
CEO, Hansa Biopharma

Thank you very much. Next page, please. In terms of where we are today, I'm extremely proud of where we are. We're well-financed, we're well-prepared for the challenges and opportunities ahead, and organizationally completely aligned to execute against a common goal, getting novel solutions to patients with a significant immunological unmet medical need. We're truly excited about the next stage of the company's development and look forward to the upcoming events. With that, I would like to open up for questions.

Operator

Thank you. If you would like to ask a question, you will need to press star, one, and one on your keypad and wait for your name to be announced. To withdraw your question, you can press star, one, and one again. We will now take our first question, which is from Farzin Haque from Jefferies. Please go ahead.

Farzin Haque
Analyst, Jefferies

Hi, everyone. Congrats on the progress, and thank you for taking my question. Maybe for Renée, can you comment on the FDA interactions so far during the review process, and have there been any specific information requests, and what is the current labeling assumptions? Do you expect the label to use a numeric threshold for the CPRA, or could it be phrased broadly as in Europe?

Renée Aguiar-Lucander
CEO, Hansa Biopharma

Thank you. Yes, the FDA interactions are progressing as expected, I would say. No particular questions that are out of the ordinary or strange. The company's been able to answer all questions that have been posed within the timeframe allotted. I wouldn't say that there are anything out of the ordinary that's been asked. We obviously cannot go in on any specific questions. In terms of the labeling, that is expected to take place according to the timelines in the guidelines, sometime over the next couple of weeks to start, or sometime over the next couple of weeks. So, in terms of expectations, I guess we'll know more once we get the first feedback from the FDA.

I guess we are hopeful that the FDA obviously will look at this in terms of the significant unmet medical need and the specific mode of action of this drug, and really allow physicians to really practice medicine and decide who within that highly sensitized group of patients should be selected for this type of treatment. As I said, we will have to wait and see what the feedback from the FDA is in that regard.

Farzin Haque
Analyst, Jefferies

Thank you. Looking forward to it.

Operator

Thank you. We'll now take the next question. This is from Thomas Smith from Leerink Partners. Please go ahead.

Thomas Smith
Analyst, Leerink Partners

Hey, team. Good morning. Thanks for taking the questions, and congrats on all the progress here. Just a follow-up on the last question. We're about five weeks out from the PDUFA date. Just wondering if you could provide an update on some of the FDA activities with respect to the pre-approval inspection of the CMC manufacturing, if that's been scheduled or completed. Then, as a follow-up question, just wondering, with respect to some of the payer discussions and expectations there, could you just talk about your expectations for how those coverage decision timelines are going to evolve here over the next 12- 24 months after launch, and I guess just the breadth of coverage and how quickly you expect to get to those decisions? Thank you so much.

Renée Aguiar-Lucander
CEO, Hansa Biopharma

Sure. Thank you. With regards to this kind of is the same kind of category, falls in the same category, we can't really comment on specific questions or specific activities that the FDA may or may not be kind of conducting as part of the review. But with regards to the payer timeline and questions around coverage of the different models, I'll hand over to Maria.

Maria Törnsén
COO and U.S. President, Hansa Biopharma

Yes. Thank you, Renée, and thank you for the question. I think there are a couple of things here to highlight. The first one is when we talk about Medicare Fee-for-Service, that is pretty straightforward in terms of the DRG plus the outlier payments, which will be applied immediately at launch. As I mentioned earlier, we have applied for NTAP, and assuming that gets approved, which we believe it will based on the profile of imlifidase, that will come into effect of October 1st, 2027. So that is sort of for Medicare Fee-for-Service. For patients that then have an insurance that fall under either sort of a Medicare Advantage or a commercial plan, there's sort of two paths, I guess, here, is one, the hospitals can do single case agreements for unique patients, which we expect that will likely happen early in the launch.

Then obviously, these plans can over time develop policies like they do for any drugs, and how they will cover that. Today, they have policies that cover transplant services, so those policies likely will evolve, and that could take could be a couple of months, it could be six months, depending on the plan, really. Then I would say the third piece that is important to keep in mind is that some hospitals would want to put the product on formulary, and that process itself can take up to six months in some institutions, and some it will be quicker. That really depends institution to institution. So that is why I said earlier when I said, I expect that these coverage decisions will evolve over time, over the next sort of six, nine months to show that we have full coverage.

But early on in the launch, you can do the single case agreements, as I mentioned, or do the traditional sort of DRG plus outlier payments to CMS.

Thomas Smith
Analyst, Leerink Partners

That is helpful. Thanks for taking the questions, and looking forward to the FDA decision next month.

Operator

Thank you. The next question today is from Chiara Montironi from Van Lanschot Kempen. Please go ahead.

Chiara Montironi
Analyst, Van Lanschot Kempen

Hello, team. Congratulations with the progress, and thank you for taking my question. I was wondering, could you perhaps share more color on how the U.S. launch trajectory could look like? Will it be initial uptake in the 25 ConfIdeS centers, or more in the 40 sites that you identified during the pre-launch efforts, and then building this out?

Renée Aguiar-Lucander
CEO, Hansa Biopharma

I think obviously this is something that, considering that we are launching kind of a first-in-class product into a patient group that really has not really been addressed previously, being very specific on launch curves is always a little bit challenging early on. But in terms of kind of the waves, if you want to call it that, in terms of how we're going to address this, I'll hand over to Maria.

Maria Törnsén
COO and U.S. President, Hansa Biopharma

Yes. Thank you for the question. I think it is realistic, like Renée said, to consider that this is a novel product entering a transplant market that hasn't really seen a new therapy launched in probably 15 years. And this is a bit of a building the market as we launch the product. I would expect that there are two factors influencing sort of the uptake. I think the first one is clinical experience. Centers that have clinical experience, I expect them to be quicker at adopting this drug. They understand the mode of action, and they understand the patient profile and how to use imlifidase. The second factor is obviously the operational and financial aspects on how they will incorporate the product into their transplant protocol and how their financial stakeholders will be sort of updating how they charge CMS for a new therapy.

My expectation is that you'll see a gradual uptake. You'll have some of these early centers that have a high volume of patients that may have participated in ConfIdeS, that have a quite sophisticated sort of infrastructure, that have an HLA lab on site, things like that. And then I expect that as we get into more sort of coverage from the market access side and with NTAP approval in Q3 2027, that that will sort of give us an additional sort of impact on the uptake curve.

Renée Aguiar-Lucander
CEO, Hansa Biopharma

Yeah, I think we kind of mentioned this before. I would say that it is probably not possible to really judge the launch or kind of the design of the launch curve in the first three months. But I would say that over the initial nine months of experience, I think we will have a very good idea of how that kind of launch curve most likely will develop. That, I think, also comes down to some of what Maria said in terms of just some of the logistics and technicalities around getting the product kind of into the hospitals. But that is obviously outweighed by the fact that we do have quite a lot of physicians asking us when the drug actually will be approved, as they have clearly kind of identified some of these patients who they believe might benefit from the treatment.

Chiara Montironi
Analyst, Van Lanschot Kempen

Clear. Thank you so much.

Operator

Thank you. Next question comes from Matthew Phipps, William Blair. Please go ahead.

Matthew Phipps
Analyst, William Blair

Hello. Thanks for taking my question, and appreciate all the additional commercial preparedness detail today. I was curious, do you guys know if you will recognize revenue as it is shipped to the hospital or when used in a patient? I guess, how many of the hospitals, the transplant centers you outlined, do you expect to stock imlifidase, maybe within those first couple months, or does that also take a time to roll out? Then for the GBS plans, the phase IIa study, just curious, how much follow-up will you need from the single ascending dose study before having sufficient data to roll into the phase III portion? Thank you.

Renée Aguiar-Lucander
CEO, Hansa Biopharma

Sure. I'll hand over to Maria and potentially Adam for the first one, and leave the second one to Richard.

Maria Törnsén
COO and U.S. President, Hansa Biopharma

Yes. Thank you. Thank you for the question. As I mentioned earlier, we have identified a specialty distributor that we will be selling to. From our perspective, we are recognizing revenue when it reaches the specialty distributor. They will then distribute or sell the product to the U.S. transplant centers. That is, in general, how we expect this to happen. As in any product launch, there could obviously be hospitals that may want to do separate agreements or contracting, and then that will be sort of a different revenue recognition model. I'll hand over to Adam if there's anything he wants to add on that comment.

Adam Cutler
CFO, Hansa Biopharma

I think Maria covered it well. Yes.

Renée Aguiar-Lucander
CEO, Hansa Biopharma

Richard, do you want to maybe address the GBS question?

Richard Philipson
CMO, Hansa Biopharma

Sure. In terms of the GBS study, the first study, the phase II-A study, is primarily focused on safety. It is a single-dose study focused on safety. The follow-up, we will include some efficacy outcomes, but nevertheless, it is focused on safety. So the follow-up will be relatively short and will allow us to move forward into the sort of phase III pivotal program. So that would be a period of three to six months potentially.

Matthew Phipps
Analyst, William Blair

Great. Thank you.

Operator

Thank you. We will now take the next question. This is from David Nierengarten, Wedbush Securities. Please go ahead.

David Nierengarten
Analyst, Wedbush Securities

Okay. Thanks for taking the question. Maybe looking longer term, you mentioned in one of the slides, I think, that you are looking at living donors, of course, and I noticed that the Australia patient was transplanted with a living donor. I was just curious if you have an idea of the regulatory pathway to add that in the United States to the label in, again, longer term. Would you need to run a new study or kind of how you are planning for that? Thank you.

Renée Aguiar-Lucander
CEO, Hansa Biopharma

Yes. With regards to, you are correct. Obviously, the drug is approved for living donors in Australia, and that is taking place. With regards to the U.S., what we are planning to do is subsequent to an approval, we do want to go back to the FDA and explore what the requirements would be for label expansion, probably initially into other solid organs, because obviously this mode of action is not organ-specific in terms of the IgG cleaving. So we would like to try and understand what the FDA would require in order for us to do that. I think that subsequent to understanding what the other solid organ path would look like, we may also certainly have separate conversation also about living donors.

Obviously, this is something where having a registry and collecting some other information is very helpful under any circumstance. This is why we are excited about the fact that we have this ability to collect this type of information as well in Australia.

Operator

Thank you. We will now move to the next question. This is from Gonzalo Artiach from Danske Bank. Please go ahead.

Gonzalo Artiach
Analyst, Danske Bank

Hi. Thank you for taking my questions. Gonzalo Artiach from Danske Bank. I have a couple of them. The first one on the GBS program, and I do not know if you could give us some color on that program, the GBS studies, since it seems that now it is moving forward. I was curious particularly on treatment windows and the key endpoints, and also what would you need to see to move into the pivotal phase? Also on the same topic, could you give us a sense on how R&D costs should develop in 2027 as the GBS program moves forward? Another question is on the U.S. kidney care reforms. We saw a few weeks ago that the HHS in the U.S. launched its Kidney Care National Plan with a focus on expanding access to transplantation.

I was just wondering what your read is on that and whether you see any practical implications for Hansa's U.S. launch. Thank you so much.

Renée Aguiar-Lucander
CEO, Hansa Biopharma

With regards to GBS, obviously, as Richard mentioned, this is more of a safety with some degree of efficacy trial that we're initiating now. With regards to the pivotal design, that is something that we've spent a lot of time actually with the FDA on, and for competitive reasons, we're not really going to address that until we are well into that trial, is our view. I don't know if, Richard, if you want to add something with regards to GBS for this particular study.

Richard Philipson
CMO, Hansa Biopharma

No. As you say, for the first study, as I mentioned previously, was primarily focused on efficacy. My apologies, primarily focused on safety. It does have some efficacy outcomes included in it, but because it's a relatively small sample size, the main focus is safety. So, in accordance with that, we would expect to see acceptable safety with evidence of pharmacodynamic effect in terms of IgG cleavage, which we would absolutely expect to see in the study, given that we've already conducted a study in healthy volunteers where we evaluated the PD of HNSA-5487 and saw appropriate effects. So those are the outcomes that we would expect to see in the study that would lead us then to move into our pivotal study.

Renée Aguiar-Lucander
CEO, Hansa Biopharma

With regards to R&D, I will say that we're actually presently refining and working on the final budget for next year. But Adam, I don't know if you want to give any high-level indications at this stage.

Adam Cutler
CFO, Hansa Biopharma

I agree that we're kind of working on refining those estimates. I do not think we expect there to be a dramatic increase in R&D, though there will be obviously some spending related to the HNSA-5487 program, while there are other elements of R&D that, as you've seen, have been sort of tailing off as we've been wrapping up some of the imlifidase-related R&D work.

Renée Aguiar-Lucander
CEO, Hansa Biopharma

With regards to the kidney reforms, I am going to hand over to Maria to potentially comment on that.

Maria Törnsén
COO and U.S. President, Hansa Biopharma

Yes. No, I think in general what I would say is that there are some positive sort of movements within the kidney care in the U.S. We previously talked about how this current administration talks a lot about increasing number of transplants, making sure that organs are better utilized, and making sure that the long-term outcomes are better for patients with transplants. In particular for this plan that was issued, I think a couple of weeks ago, I think it is very positive for us because it highlights a couple of things. One being the economic benefit, which they estimate to, I think, $4.7 million per kidney transplant. They also talked about the expected sort of increase in lifespan for patients that go through kidney transplantation.

They also talked about the number of hours that are saved each year per patient, compared to going to a dialysis clinic and traveling to treatment, and they estimate that to 671 hours each year. They also talked about how these policies to increase kidney transplantation could actually generate between $100 billion and $200 billion in economic benefits through 2040. All of that is positive because it really highlights the importance of getting patients off dialysis and onto transplant. From an imlifidase perspective, entering sort of into that space with a new novel drug that potentially could enable more patients to get transplanted, I think is all in favor of us. I am really pleased to see the efforts that are happening on the policy side in the U.S.

Gonzalo Artiach
Analyst, Danske Bank

Thank you so much.

Operator

Thank you. As a reminder, if you would like to ask a question, you will need to press star, one, and one on your telephone and wait for your name to be announced. To withdraw your question, you can press star, one, and one again. Next question today comes from Ludvig Svensson from ABG Sundal Collier. Please go ahead.

Ludvig Svensson
Analyst, ABG Sundal Collier

Yeah. Thank you very much, Hansa team, for taking my questions. You touched on this a little bit, but with the potential launch in the U.S. coming up, I was wondering on how many centers you plan to target in the initial phase, and also how many centers you target to be active in a more mature stage?

Renée Aguiar-Lucander
CEO, Hansa Biopharma

Maria, do you want to take that?

Maria Törnsén
COO and U.S. President, Hansa Biopharma

Yes. In the U.S., we have 200 transplant centers that do kidney transplants for adults. Our initial focus is on the tier one centers, which is the 100 centers that represent 80% of the volume. Among those 100, we have the 25 ConfIdeS centers. Our team today, our medical and our market access team, they are focusing on those 100 centers to get them ready to use the drug. I think once we get through those 100, we will probably focus on the next 100. The 100 centers are the initial focus.

Ludvig Svensson
Analyst, ABG Sundal Collier

Right. Perfect. That makes sense. Thank you. What do you believe, do you have any idea on the average annual capacity in the U.S. per center? What is the limit to how many patients you can treat with imlifidase-enabled transplantations?

Renée Aguiar-Lucander
CEO, Hansa Biopharma

I have not personally heard of anyone who says that there is a physical or technical limit on kind of number of transplants that they can do. I do not know, Maria, if you have a different-

Maria Törnsén
COO and U.S. President, Hansa Biopharma

No. That is not a limiting factor. There is nothing. I have met with many physicians, both at ConfIdeS centers and non-ConfIdeS centers, and none of them have highlighted that capacity is an issue. I do not foresee that becoming anything that will impact us.

Ludvig Svensson
Analyst, ABG Sundal Collier

Okay, great. That was all for me. Thank you very much.

Maria Törnsén
COO and U.S. President, Hansa Biopharma

Thanks.

Operator

Thank you. The last question today comes from Richard Ramanius from Redeye. Please go ahead.

Richard Ramanius
Analyst, Redeye

Hello. Good afternoon. Just the one question. What is the status of the gene therapy collaborations and the Sarepta program in particular? Thanks.

Renée Aguiar-Lucander
CEO, Hansa Biopharma

Yes. In terms of the gene therapy, what we've done is obviously we've recently added some business development resources. A part of that remit really is to spend the next 12 months or so exploring the broader gene therapy opportunity for the company, with a view to hopefully entering into additional collaborations over that period of time. With regards to Sarepta, obviously they are really, I guess, in a bit of a hold due to their own drug-related situation in terms of interactions with the FDA, et cetera. There's really been no change in that status over the last three months.

Richard Ramanius
Analyst, Redeye

Great. Thanks for answering my question.

Operator

Thank you. There are no further questions at this time, so I will now hand back to Renée for any closing comments.

Renée Aguiar-Lucander
CEO, Hansa Biopharma

Well, thank you very much for listening to our Q3 2026 interim report. We certainly look forward to catching up with you later on in the year when we have the decision from the FDA regarding our PDUFA. Thank you very much.

Operator

Thank you. This concludes today's conference call. Thank you for participating, and you may now disconnect. Speakers, please stand by.